ClinicalTrials.gov
public full text
Public Domain
Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies
Omidubicel is an investigational therapy for patients with high-risk hematologic malignancies.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS#1260335
- Allogeneic Cell Therapy for Adults With Hematologic Malignancies#836546
- Allo After Allo Stem Cell Transplantation Following Relapse After Allogeneic Transplant in Haematological Malignancies: Retrospective Results of the GETH#803136
- Sorafenib for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3-ITD Positive AML#1369455
- A Randomized Multicenter Study to Compare Two Types of Transplant in Adult Patients With Hematologic Malignancies#1100705
Record · ID 1371744
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive